{{Rsnum
|rsid=1883112
|Gene=NCF4
|Chromosome=22
|position=36860804
|Orientation=plus
|GMAF=0.4458
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NCF4
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 18.6 | 53.1 | 28.3
| HCB | 54.0 | 35.8 | 10.2
| JPT | 38.1 | 44.2 | 17.7
| YRI | 0.7 | 15.6 | 83.7
| ASW | 3.5 | 47.4 | 49.1
| CHB | 54.0 | 35.8 | 10.2
| CHD | 58.7 | 33.9 | 7.3
| GIH | 20.8 | 45.5 | 33.7
| LWK | 0.9 | 33.6 | 65.5
| MEX | 31.0 | 50.0 | 19.0
| MKK | 8.3 | 39.7 | 51.9
| TSI | 6.9 | 57.8 | 35.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1883112
|Name_s=NCF4  -212A>G
|Gene_s=NCF4
|Feature=
|Evidence=PubMed ID:16330681
|Annotation=Risk or phenotype-associated allele: AA. Phenotype: Homozygous AA at this SNP was associated with chronic cardiotoxicity in response to doxorubicin. Study size: 1697. Study population/ethnicity: Participants of the German non-Hodgkin lymphoma study. Significance metric(s): OR = 2.5; 95% CI, 1.3 to 5.0. Type of association: PD; ADR; TOX.
|Drugs=doxorubicin
|Drug Classes=
|Diseases=Cardiomyopathies; Drug Toxicity; Heart Failure; Lymphoma, Non-Hodgkin
|Curation Level=Curated
|PharmGKB Accession ID=PA165291815
}}

{{PMID Auto
|PMID=19448608
|Title=Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1883112
|overall_frequency_n=38
|overall_frequency_d=128
|overall_frequency=0.296875
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23576480
|Title=Association of Anthracycline-Related Cardiac Histological Lesions With NADPH Oxidase Functional Polymorphisms
|OA=1
}}

{{PMID Auto
|PMID=24633940
|Title=Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}